The genomic and proteomic tool market size has grown rapidly in recent years. It will grow from $33.14 billion in 2025 to $37 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising genomic research funding, expansion of NGS technologies, growth in pharmaceutical R&D, increasing academic research activities, declining sequencing costs.
The genomic and proteomic tool market size is expected to see rapid growth in the next few years. It will grow to $56.95 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growth of precision medicine, increasing clinical genomics adoption, rising demand for proteomics in drug discovery, expansion of personalized diagnostics, advancements in bioinformatics tools. Major trends in the forecast period include high-throughput sequencing adoption, integrated multi-omics platforms, automation in sample preparation, growth of cloud-based bioinformatics, expansion of biomarker discovery.
The rising adoption of personalized medicine is expected to drive the growth of the genomic and proteomic tool market in the coming years. Personalized medicine customizes prevention, diagnosis, and treatment based on an individual’s molecular profile using biomarkers from DNA, RNA, and proteins. This trend is fueled by advances in genomics, proteomics, and biomarker discovery, which enable tailored treatments, targeted therapies, improved diagnostics, and precision healthcare solutions. Genomic and proteomic tools are essential in this process, as they identify genetic variations and protein biomarkers, helping clinicians optimize treatments and enhance patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition reported that the USFDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, highlighting the increasing adoption of personalized medicine and its role in driving the genomic and proteomic tool market.
Companies in the genomic and proteomic tools market are increasingly investing in spatial multi-omics technologies, which allow for the in-situ detection of RNA and proteins within the same cell, thereby integrating molecular data layers and preserving tissue architecture. This approach, known as spatial multi-omics, enables the measurement of gene expression and protein markers at single-cell or subcellular resolution, providing deeper biological insights than traditional single-modality tests. For instance, in August 2025, 10x Genomics, a US-based biotech company, launched Xenium Protein, a groundbreaking assay for single-cell RNA and protein analysis on the Xenium in situ platform. This solution simplifies workflows by eliminating the need for cross-platform data integration and comes with pre-validated protein subpanels for easier setup and quality control. These innovations enhance the ability to maintain spatial context while expanding biomarker panels for applications such as target validation, patient stratification, and mechanism-of-action studies.
In July 2024, Thermo Fisher Scientific Inc., a US-based biotech company, acquired Olink Holding AB to bolster its proteomics portfolio. This acquisition integrates Olink’s proximity extension assay (PEA) platform into Thermo Fisher’s Life Sciences Solutions segment, strengthening its capabilities in high-plex protein biomarker discovery and quantification. This acquisition complements Thermo Fisher’s existing mass spectrometry and sequencing technologies and accelerates progress in translational research and the development of companion diagnostics. Olink Holding AB, a company based in Sweden, is known for its next-generation proteomics tools and solutions.
Major companies operating in the genomic and proteomic tool market are F. HoffmannLa Roche, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, GE Healthcare, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., PerkinElmer Inc., Promega, Novogene Corp., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Sophia Genetics, LC Sciences.
North America was the largest region in the genomic and proteomic tool market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic and proteomic tool market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic and proteomic tool market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the genomic and proteomic tool market by increasing costs of imported instruments, reagents, and precision components, particularly impacting sequencing and mass spectrometry segments. North America and Europe face supply pressures due to reliance on Asia-Pacific manufacturing hubs. Higher prices have slowed adoption in cost-sensitive research institutions. However, tariffs are encouraging local manufacturing, regional supplier development, and innovation in cost-efficient genomic and proteomic solutions.
The genomic and proteomic tool market research report is one of a series of new reports that provides genomic and proteomic tool market statistics, including genomic and proteomic tool industry global market size, regional shares, competitors with a genomic and proteomic tool market share, detailed genomic and proteomic tool market segments, market trends and opportunities, and any further data you may need to thrive in the genomic and proteomic tool industry. This genomic and proteomic tool market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Genomic and proteomic tools comprise advanced methods and technologies used to investigate the complete set of genes (genome) and proteins (proteome) in an organism. Genomic tools analyze DNA and RNA to explore gene sequences, expression patterns, mutations, and interactions, utilizing techniques such as DNA sequencing, PCR, microarrays, and genome editing. Proteomic tools focus on protein structure, function, abundance, and interactions through methods including mass spectrometry, 2D gel electrophoresis, and protein microarrays.
The primary product categories of genomic and proteomic tools include instruments, consumables, software, and services. Instruments are specialized devices designed to measure, detect, separate, or manipulate physical or molecular properties in laboratory samples, allowing precise observation and control beyond human capabilities, covering areas from microscopy to analytical measurement. The technologies involved include sequencing, microarrays, polymerase chain reaction (PCR), and chromatography, which operate through stages of sample preparation, library preparation, data analysis, and reporting. Applications extend to drug discovery, diagnostics, personalized medicine, agriculture, and animal research.
The genomic and proteomic tool market consists of revenues earned by entities by providing services such as DNA sequencing systems, gene expression analysis platforms, microarray technologies, and mass spectrometry systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic and proteomic tools market also includes sales of electrophoresis equipment, and chromatography instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The genomic and proteomic tool market size is expected to see rapid growth in the next few years. It will grow to $56.95 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growth of precision medicine, increasing clinical genomics adoption, rising demand for proteomics in drug discovery, expansion of personalized diagnostics, advancements in bioinformatics tools. Major trends in the forecast period include high-throughput sequencing adoption, integrated multi-omics platforms, automation in sample preparation, growth of cloud-based bioinformatics, expansion of biomarker discovery.
The rising adoption of personalized medicine is expected to drive the growth of the genomic and proteomic tool market in the coming years. Personalized medicine customizes prevention, diagnosis, and treatment based on an individual’s molecular profile using biomarkers from DNA, RNA, and proteins. This trend is fueled by advances in genomics, proteomics, and biomarker discovery, which enable tailored treatments, targeted therapies, improved diagnostics, and precision healthcare solutions. Genomic and proteomic tools are essential in this process, as they identify genetic variations and protein biomarkers, helping clinicians optimize treatments and enhance patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition reported that the USFDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, highlighting the increasing adoption of personalized medicine and its role in driving the genomic and proteomic tool market.
Companies in the genomic and proteomic tools market are increasingly investing in spatial multi-omics technologies, which allow for the in-situ detection of RNA and proteins within the same cell, thereby integrating molecular data layers and preserving tissue architecture. This approach, known as spatial multi-omics, enables the measurement of gene expression and protein markers at single-cell or subcellular resolution, providing deeper biological insights than traditional single-modality tests. For instance, in August 2025, 10x Genomics, a US-based biotech company, launched Xenium Protein, a groundbreaking assay for single-cell RNA and protein analysis on the Xenium in situ platform. This solution simplifies workflows by eliminating the need for cross-platform data integration and comes with pre-validated protein subpanels for easier setup and quality control. These innovations enhance the ability to maintain spatial context while expanding biomarker panels for applications such as target validation, patient stratification, and mechanism-of-action studies.
In July 2024, Thermo Fisher Scientific Inc., a US-based biotech company, acquired Olink Holding AB to bolster its proteomics portfolio. This acquisition integrates Olink’s proximity extension assay (PEA) platform into Thermo Fisher’s Life Sciences Solutions segment, strengthening its capabilities in high-plex protein biomarker discovery and quantification. This acquisition complements Thermo Fisher’s existing mass spectrometry and sequencing technologies and accelerates progress in translational research and the development of companion diagnostics. Olink Holding AB, a company based in Sweden, is known for its next-generation proteomics tools and solutions.
Major companies operating in the genomic and proteomic tool market are F. HoffmannLa Roche, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, GE Healthcare, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., PerkinElmer Inc., Promega, Novogene Corp., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Sophia Genetics, LC Sciences.
North America was the largest region in the genomic and proteomic tool market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic and proteomic tool market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic and proteomic tool market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the genomic and proteomic tool market by increasing costs of imported instruments, reagents, and precision components, particularly impacting sequencing and mass spectrometry segments. North America and Europe face supply pressures due to reliance on Asia-Pacific manufacturing hubs. Higher prices have slowed adoption in cost-sensitive research institutions. However, tariffs are encouraging local manufacturing, regional supplier development, and innovation in cost-efficient genomic and proteomic solutions.
The genomic and proteomic tool market research report is one of a series of new reports that provides genomic and proteomic tool market statistics, including genomic and proteomic tool industry global market size, regional shares, competitors with a genomic and proteomic tool market share, detailed genomic and proteomic tool market segments, market trends and opportunities, and any further data you may need to thrive in the genomic and proteomic tool industry. This genomic and proteomic tool market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Genomic and proteomic tools comprise advanced methods and technologies used to investigate the complete set of genes (genome) and proteins (proteome) in an organism. Genomic tools analyze DNA and RNA to explore gene sequences, expression patterns, mutations, and interactions, utilizing techniques such as DNA sequencing, PCR, microarrays, and genome editing. Proteomic tools focus on protein structure, function, abundance, and interactions through methods including mass spectrometry, 2D gel electrophoresis, and protein microarrays.
The primary product categories of genomic and proteomic tools include instruments, consumables, software, and services. Instruments are specialized devices designed to measure, detect, separate, or manipulate physical or molecular properties in laboratory samples, allowing precise observation and control beyond human capabilities, covering areas from microscopy to analytical measurement. The technologies involved include sequencing, microarrays, polymerase chain reaction (PCR), and chromatography, which operate through stages of sample preparation, library preparation, data analysis, and reporting. Applications extend to drug discovery, diagnostics, personalized medicine, agriculture, and animal research.
The genomic and proteomic tool market consists of revenues earned by entities by providing services such as DNA sequencing systems, gene expression analysis platforms, microarray technologies, and mass spectrometry systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic and proteomic tools market also includes sales of electrophoresis equipment, and chromatography instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Genomic and Proteomic Tool Market Characteristics
3. Genomic and Proteomic Tool Market Supply Chain Analysis
4. Global Genomic and Proteomic Tool Market Trends and Strategies
5. Genomic and Proteomic Tool Market Analysis of End Use Industries
7. Global Genomic and Proteomic Tool Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Genomic and Proteomic Tool Total Addressable Market (TAM) Analysis for the Market
9. Genomic and Proteomic Tool Market Segmentation
10. Genomic and Proteomic Tool Market Regional and Country Analysis
11. Asia-Pacific Genomic and Proteomic Tool Market
12. China Genomic and Proteomic Tool Market
13. India Genomic and Proteomic Tool Market
14. Japan Genomic and Proteomic Tool Market
15. Australia Genomic and Proteomic Tool Market
16. Indonesia Genomic and Proteomic Tool Market
17. South Korea Genomic and Proteomic Tool Market
18. Taiwan Genomic and Proteomic Tool Market
19. South East Asia Genomic and Proteomic Tool Market
20. Western Europe Genomic and Proteomic Tool Market
21. UK Genomic and Proteomic Tool Market
22. Germany Genomic and Proteomic Tool Market
23. France Genomic and Proteomic Tool Market
24. Italy Genomic and Proteomic Tool Market
25. Spain Genomic and Proteomic Tool Market
26. Eastern Europe Genomic and Proteomic Tool Market
27. Russia Genomic and Proteomic Tool Market
28. North America Genomic and Proteomic Tool Market
29. USA Genomic and Proteomic Tool Market
30. Canada Genomic and Proteomic Tool Market
31. South America Genomic and Proteomic Tool Market
32. Brazil Genomic and Proteomic Tool Market
33. Middle East Genomic and Proteomic Tool Market
34. Africa Genomic and Proteomic Tool Market
36. Genomic and Proteomic Tool Market Competitive Landscape and Company Profiles
37. Genomic and Proteomic Tool Market Other Major and Innovative Companies
40. Genomic and Proteomic Tool Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Genomic And Proteomic Tool Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses genomic and proteomic tool market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for genomic and proteomic tool? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The genomic and proteomic tool market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Instruments; Consumables; Software; Services2) By Technology: Sequencing; Microarray; Polymerase Chain Reaction (PCR); Mass Spectrometry; Electrophoresis; Chromatography
3) By Workflow Stage: Sample Preparation; Library Preparation; Data Analysis; Reporting
4) By Application: Drug Discovery; Diagnostics; Personalized Medicine; Agriculture And Animal Research
5) By End User: Academic And Research Institutions; Pharmaceutical And Biotechnology Companies; Diagnostic Laboratories; Healthcare Providers
Subsegments:
1) By Instruments: DNA Sequencing Systems; Polymerase Chain Reaction (PCR) Systems; Microarray Analyzers; Mass Spectrometry Instruments; Electrophoresis Systems; Chromatography Instruments; Flow Cytometers2) By Consumables: Reagents And Kits; Assay Kits; Sample Preparation Consumables; Sequencing Consumables; Protein Assay Reagents; Microarray Chips; Laboratory Chemicals
3) By Software: Genomic Data Analysis Software; Proteomic Data Analysis Software; Bioinformatics Platforms; Clinical Data Interpretation Tools; Workflow Management Software; Cloud-based Analysis Platforms
4) By Services: Next-Generation Sequencing (NGS) Services; Gene Expression And Genotyping Services; Protein Identification And Quantification Services; Biomarker Discovery Services; Structural Biology Analysis Services; Bioinformatics And Data Interpretation Services; Molecular Diagnostics Services
Companies Mentioned: F. HoffmannLa Roche; Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Becton Dickinson and Company; GE Healthcare; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Bruker Corporation; Waters Corporation; Bio-Rad Laboratories Inc.; QIAGEN N.V.; PerkinElmer Inc.; Promega; Novogene Corp.; Oxford Nanopore Technologies Ltd.; Pacific Biosciences of California Inc.; Sophia Genetics; LC Sciences
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Genomic and Proteomic Tool market report include:- F. HoffmannLa Roche
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Merck KGaA
- Becton Dickinson and Company
- GE Healthcare
- Eurofins Scientific SE
- Agilent Technologies Inc.
- Illumina Inc.
- Bruker Corporation
- Waters Corporation
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- PerkinElmer Inc.
- Promega
- Novogene Corp.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
- Sophia Genetics
- LC Sciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 37 Billion |
| Forecasted Market Value ( USD | $ 56.95 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
